These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8842156)

  • 1. p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells.
    Mullick SS; Green LK; Ramzy I; Brown RW; Smith D; Gondo MM; Cagle PT
    Acta Cytol; 1996; 40(5):855-60. PubMed ID: 8842156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
    Cagle PT; Brown RW; Lebovitz RM
    Hum Pathol; 1994 May; 25(5):443-8. PubMed ID: 8200637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
    Hafez NH; Tahoun NS
    J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.
    Stoetzer OJ; Munker R; Darsow M; Wilmanns W
    Oncol Rep; 1999; 6(2):455-8. PubMed ID: 10023021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry.
    Queiroz C; Barral-Netto M; Bacchi CE
    Acta Cytol; 2001; 45(1):18-22. PubMed ID: 11213499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology.
    Mayall F; Heryet A; Manga D; Kriegeskotten A
    Cytopathology; 1997 Feb; 8(1):9-12. PubMed ID: 9068950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.
    Morgan RL; De Young BR; McGaughy VR; Niemann TH
    Cancer; 1999 Dec; 87(6):390-4. PubMed ID: 10603193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
    Hyun TS; Barnes M; Tabatabai ZL
    Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 immunolocalization in cell block preparations of squamous lesions of the neck: an adjunct to fine-needle aspiration diagnosis of malignancy.
    Khurana KK; Ramzy I; Truong LD
    Arch Pathol Lab Med; 1999 May; 123(5):421-5. PubMed ID: 10235501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of p53 protein in the study of serous effusions.
    Zoppi JA; Pellicer EM; Sundblad AS
    Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of Ki67 immunostain in identification of malignancy in serous effusions.
    Saleh H; Bober P; Tabaczka P
    Diagn Cytopathol; 1999 Jan; 20(1):24-8. PubMed ID: 9884823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
    Rakha EA; Patil S; Abdulla K; Abdulkader M; Chaudry Z; Soomro IN
    Diagn Cytopathol; 2010 Dec; 38(12):874-9. PubMed ID: 20049969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant pleural effusions due to small-cell lung carcinoma: a cytologic and immunocytochemical study.
    Chhieng DC; Ko EC; Yee HT; Shultz JJ; Dorvault CC; Eltoum IA
    Diagn Cytopathol; 2001 Dec; 25(6):356-60. PubMed ID: 11747231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic yield of pleural fluid cytology in malignant pleural effusions.
    Ong KC; Indumathi V; Poh WT; Ong YY
    Singapore Med J; 2000 Jan; 41(1):19-23. PubMed ID: 10783675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
    Mayall FG; Goddard H; Gibbs AR
    J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
    Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
    Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoperoxidase staining of malignant cells in pleural effusions.
    Pastormerlo M
    Pathologica; 1990; 82(1080):421-5. PubMed ID: 2284143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.